Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[64Cu]IS3000 is a copper-64-labeled radiopharmaceutical PET imaging agent developed by iSeek Biopharma. It targets lymphocyte function-associated antigen 1 (LFA-1), a cell-surface glycoprotein expressed on leukocytes. By binding to LFA-1, [64Cu]IS3000 enables the visualization of activated immune cells in vivo. The candidate is being developed under two programs: the TRUVIEW program for next-generation infection and inflammation imaging, and the ORION program as a diagnostic imaging arm paired with therapeutic radiopharmaceuticals (such as [177Lu]IS3010 and [225Ac]IS3010) for immuno-oncology theranostics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [64Cu]IS3000.